Weiss Ratings Reiterates "Hold (C-)" Rating for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Key Points

• Weiss Ratings has reiterated a "Hold (C-)" rating for Amphastar Pharmaceuticals, indicating a cautious stance from analysts.
• The consensus rating for Amphastar Pharmaceuticals is "Moderate Buy," with a price target of $31.60 following various analysts' ratings.
• Amphastar's stock price recently traded down to $24.52, with significant trading volume of 138,262 shares on the latest trading day.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report)'s stock had its "hold (c-)" rating reissued by equities research analysts at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports.

A number of other research firms have also recently commented on AMPH. Needham & Company LLC reissued a "buy" rating and set a $36.00 price target on shares of Amphastar Pharmaceuticals in a report on Wednesday. Zacks Research raised Amphastar Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Thursday, October 16th. Piper Sandler reduced their target price on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating on the stock in a report on Friday, August 8th. Finally, Bank of America lifted their target price on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a "neutral" rating in a report on Tuesday, August 26th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Amphastar Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $31.60.

Amphastar Pharmaceuticals Price Performance

NASDAQ:AMPH traded down $0.21 on Friday, reaching $24.52. 138,262 shares of the company's stock traded hands, compared to its average volume of 543,339. The company has a quick ratio of 2.21, a current ratio of 3.29 and a debt-to-equity ratio of 0.80. The stock has a 50-day simple moving average of $27.43 and a 200-day simple moving average of $25.20. The firm has a market cap of $1.14 billion, a PE ratio of 9.18 and a beta of 0.75. Amphastar Pharmaceuticals has a 12 month low of $20.39 and a 12 month high of $53.96.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Cambridge Investment Research Advisors Inc. increased its stake in Amphastar Pharmaceuticals by 14.0% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 13,790 shares of the company's stock worth $400,000 after acquiring an additional 1,694 shares during the last quarter. Picton Mahoney Asset Management increased its stake in Amphastar Pharmaceuticals by 6,600.0% during the first quarter. Picton Mahoney Asset Management now owns 1,608 shares of the company's stock worth $46,000 after acquiring an additional 1,584 shares during the last quarter. Graham Capital Management L.P. bought a new stake in Amphastar Pharmaceuticals during the first quarter worth approximately $766,000. Allspring Global Investments Holdings LLC increased its stake in Amphastar Pharmaceuticals by 9.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 15,326 shares of the company's stock worth $434,000 after acquiring an additional 1,262 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in Amphastar Pharmaceuticals during the first quarter worth approximately $532,000. 65.09% of the stock is owned by institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.